407 related articles for article (PubMed ID: 30645669)
1. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
Durot C; Mulé S; Soyer P; Marchal A; Grange F; Hoeffel C
Eur Radiol; 2019 Jun; 29(6):3183-3191. PubMed ID: 30645669
[TBL] [Abstract][Full Text] [Related]
2. CT texture analysis as a predictor of favorable response to anti-PD1 monoclonal antibodies in metastatic skin melanoma.
Bonnin A; Durot C; Barat M; Djelouah M; Grange F; Mulé S; Soyer P; Hoeffel C
Diagn Interv Imaging; 2022 Feb; 103(2):97-102. PubMed ID: 34666945
[TBL] [Abstract][Full Text] [Related]
3. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
Mulé S; Thiefin G; Costentin C; Durot C; Rahmouni A; Luciani A; Hoeffel C
Radiology; 2018 Aug; 288(2):445-455. PubMed ID: 29584597
[TBL] [Abstract][Full Text] [Related]
4. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma: CT texture analysis as a predictor of survival after surgical resection.
Brenet Defour L; Mulé S; Tenenhaus A; Piardi T; Sommacale D; Hoeffel C; Thiéfin G
Eur Radiol; 2019 Mar; 29(3):1231-1239. PubMed ID: 30159621
[TBL] [Abstract][Full Text] [Related]
6. Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis.
Smith AD; Gray MR; del Campo SM; Shlapak D; Ganeshan B; Zhang X; Carson WE
AJR Am J Roentgenol; 2015 Sep; 205(3):W283-93. PubMed ID: 26295664
[TBL] [Abstract][Full Text] [Related]
7. Metastatic clear cell renal cell carcinoma: computed tomography texture analysis as predictive biomarkers of survival in patients treated with nivolumab.
Khene ZE; Kokorian R; Mathieu R; Gasmi A; Nathalie RL; Solène-Florence KJ; Shariat S; de Crevoisier R; Laguerre B; Bensalah K
Int J Clin Oncol; 2021 Nov; 26(11):2087-2093. PubMed ID: 34338919
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M
Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148
[TBL] [Abstract][Full Text] [Related]
9. Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach.
Guerrisi A; Russillo M; Loi E; Ganeshan B; Ungania S; Desiderio F; Bruzzaniti V; Falcone I; Renna D; Ferraresi V; Caterino M; Solivetti FM; Cognetti F; Morrone A
Front Oncol; 2021; 11():704607. PubMed ID: 34692481
[TBL] [Abstract][Full Text] [Related]
10. CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes.
Lubner MG; Stabo N; Lubner SJ; del Rio AM; Song C; Halberg RB; Pickhardt PJ
Abdom Imaging; 2015 Oct; 40(7):2331-7. PubMed ID: 25968046
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab as first-line treatment for metastatic uveal melanoma.
Rossi E; Pagliara MM; Orteschi D; Dosa T; Sammarco MG; Caputo CG; Petrone G; Rindi G; Zollino M; Blasi MA; Cassano A; Bria E; Tortora G; Schinzari G
Cancer Immunol Immunother; 2019 Jul; 68(7):1179-1185. PubMed ID: 31175402
[TBL] [Abstract][Full Text] [Related]
12. Radiomics-Based Texture Analysis of
Atkinson C; Ganeshan B; Endozo R; Wan S; Aldridge MD; Groves AM; Bomanji JB; Gaze MN
Front Oncol; 2021; 11():686235. PubMed ID: 34408979
[TBL] [Abstract][Full Text] [Related]
13. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
[No Abstract] [Full Text] [Related]
14. CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.
Haider MA; Vosough A; Khalvati F; Kiss A; Ganeshan B; Bjarnason GA
Cancer Imaging; 2017 Jan; 17(1):4. PubMed ID: 28114978
[TBL] [Abstract][Full Text] [Related]
15. Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival.
Ng F; Ganeshan B; Kozarski R; Miles KA; Goh V
Radiology; 2013 Jan; 266(1):177-84. PubMed ID: 23151829
[TBL] [Abstract][Full Text] [Related]
16. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
17. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
[TBL] [Abstract][Full Text] [Related]
18. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance.
Durot C; Durot E; Mulé S; Morland D; Godard F; Quinquenel A; Delmer A; Soyer P; Hoeffel C
Diagnostics (Basel); 2023 Jun; 13(13):. PubMed ID: 37443630
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
